1. SGLT2 inhibitors, Now Part of the Cardiology Toolkit for Comprehensive CV Risk Management

3. Introduction/Background

4. T2DM as a Risk Factor for CVD

5. Close Linkage Between T2DM and HF

6. Intensive Glycemic Control Increased All-Cause Mortality (ACCORD)[a]

7. December 2008 FDA Guidance on Evaluating CV Risk in New Antidiabetic Therapies for T2DM

8. Assessing CV Risk in Antihyperglycemic Agents: Too Broad-Brush?

9. SAVOR-TIMI 53 (Saxagliptin): Hospitalization for HF

10. EXAMINE (Alogliptin): Hospitalization for HF[a,b]

11. TECOS (Sitagliptin): Hospitalization for HF

12. CV Safety Trials for the Gliptins: What Was the Point?

13. ELIXA (Lixisenatide): Primary Outcome CV Death, Nonfatal MI, Nonfatal Stroke, or Hospitalization for UA

14. LEADER: Primary Outcome Liraglutide vs Placebo*

15. Semaglutide Results: Renal Protection

16. Empagliflozin Modulates Several Factors Related to CV Risk

17. EMPA-REG OUTCOME: Trial Design

18. EMPA-REG Primary Outcome (3-Point MACE): CV Death, Nonfatal MI, or Nonfatal Stroke

19. EMPA-REG: Results for CV Death

20. EMPA-REG: Hospitalization for HF

21. EMPA-REG Microvascular Outcomes: Renal Protection

22. Kidney Damage and SGLT2 Inhibitors

23. EMPA-REG OUTCOME: Baseline Characteristics—CV Complications

24. Don't Ignore HF in T2DM

25. Potential Mechanisms for CV Benefit Associated With Empagliflozin

26. Is There a Role for SGLT2 Inhibitors in Patients Without T2DM?

27. Are EMPA-REG Data Changing Practice Patterns?

28. EMPA-REG Outcomes: Class Effect or Agent-Specific?

29. What Explains the Macro- and Microvascular Improvements Observed in LEADER?

30. Summary and Conclusions

31. Abbreviations

32. Abbreviations (cont)